Marjorie C. Green

5.6k total citations · 1 hit paper
19 papers, 2.3k citations indexed

About

Marjorie C. Green is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marjorie C. Green has authored 19 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marjorie C. Green's work include Breast Cancer Treatment Studies (11 papers), Cancer Treatment and Pharmacology (7 papers) and HER2/EGFR in Cancer Research (6 papers). Marjorie C. Green is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), Cancer Treatment and Pharmacology (7 papers) and HER2/EGFR in Cancer Research (6 papers). Marjorie C. Green collaborates with scholars based in United States, United Kingdom and France. Marjorie C. Green's co-authors include Gabriel N. Hortobágyi, Nuhad K. Ibrahim, Lajos Pusztai, Kelly K. Hunt, Aman U. Buzdar, Richard L. Theriault, Thomas A. Buchholz, Ayşegül A. Şahin, Massimo Cristofanilli and S. Eva Singletary and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Marjorie C. Green

19 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

2005 867 citations Aman U. Buzdar, Nuhad K. Ibrahim et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Marjorie C. Green

Since Specialization

Citations

This map shows the geographic impact of Marjorie C. Green's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marjorie C. Green with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marjorie C. Green more than expected).

Fields of papers citing papers by Marjorie C. Green

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marjorie C. Green. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marjorie C. Green. The network helps show where Marjorie C. Green may publish in the future.

Co-authorship network of co-authors of Marjorie C. Green

This figure shows the co-authorship network connecting the top 25 collaborators of Marjorie C. Green. A scholar is included among the top collaborators of Marjorie C. Green based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marjorie C. Green. Marjorie C. Green is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study. 2018 ·Journal of Clinical Oncology ·Thomas Powles, Yohann Loriot, Alain Ravaud, Nicholas J. Vogelzang, Ignacio Durán, Margitta Retz, Ugo De Giorgi, Stéphane Oudard, Aristotelis Bamias, Hartmut Koeppen, Ning Leng, Edward E. Kadel, Priti S. Hegde, Na Cui, Xiaodong Shen, Christina Louise Derleth, Marjorie C. Green, Romain Banchereau, Sanjeev Mariathasan, Michiel Simon Van Der Heijden	35
2	Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC). 2018 ·Journal of Clinical Oncology ·Manuel Caitano Maia, Neeraj Agarwal, Bradley A. McGregor, Ulka N. Vaishampayan, Toni K. Choueiri, Marjorie C. Green, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas Powles, Sumanta K. Pal, (unknown)	4
3	A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). 2017 ·Journal of Clinical Oncology ·(unknown), Karim Fizazi, Silke Gillessen, Charles G. Drake, Dana E. Rathkopf, Sujata Narayanan, Marjorie C. Green, Almut Mecke, Christina Schiff, Christopher J. Sweeney	5
4	Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy 2013 ·Radiation Oncology ·Heath D. Skinner, Eric A. Strom, S.B. Motwani, Wendy A. Woodward, Marjorie C. Green, Gildy V. Babiera, Daniel J. Booser, Funda Meric‐Bernstam, Thomas A. Buchholz	21
5	Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases 2013 ·Journal of Oncology Pharmacy Practice ·(unknown), Laura Boehnke Michaud, Edgardo Rivera, Timothy Madden, (unknown), Jitesh D. Kawedia, Daniel J. Booser, Marjorie C. Green, Gabriel N. Hortobágyi, Vicente Valero	13
6	Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer 2012 ·Cancer Chemotherapy and Pharmacology ·Francisco J. Esteva, Stacy Moulder, Ana M. González-Angulo, Joe Ensor, James L. Murray, Marjorie C. Green, Kimberly B. Koenig, Mong‐Hong Lee, Gabriel N. Hortobágyi, Sai‐Ching J. Yeung	27
7	Resection of liver metastases from breast cancer: Estrogen receptor status and response to chemotherapy before metastasectomy define outcome 2012 ·Surgery ·Daniel E. Abbott, Antoine Brouquet, Elizabeth A. Mittendorf, Andréas Andreou, Funda Meric‐Bernstam, Vicente Valero, Marjorie C. Green, Henry M. Kuerer, Steven A. Curley, Eddie K. Abdalla, Kelly K. Hunt, Jean‐Nicolas Vauthey	103
8	Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer 2012 ·Journal of Clinical Oncology ·Catherine M. Kelly, Marjorie C. Green, Kristine Broglio, Eva Thomas, Abenaa M. Brewster, Vicente Valero, Nuhad K. Ibrahim, Ana M. González-Angulo, Daniel J. Booser, Ronald S. Walters, Kelly K. Hunt, Gabriel N. Hortobágyi, Aman U. Buzdar	26
9	Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting. 2012 ·Journal of Clinical Oncology ·Rashmi K. Murthy, Ankur Varma, (unknown), Kenneth R. Hess, Elliana Young, James L. Murray, (unknown), Marjorie C. Green, Stacy L. Moulder, Amal Melhem‐Bertrandt, Daniel J. Booser, Vicente Valero, Gabriel N. Hortobágyi, Francisco J. Esteva	2
10	Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers 2010 ·Journal of Clinical Oncology ·Giampaolo Bianchini, Yuan Qi, Ricardo H. Álvarez, Takayuki Iwamoto, Charles Coutant, Nuhad K. Ibrahim, Vicente Valero, Massimo Cristofanilli, Marjorie C. Green, Laszlo Radvanyi, Christos Hatzis, Gabriel N. Hortobágyi, Fabrice André, Luca Gianni, W. Fraser Symmans, Lajos Pusztai	170
11	Fast dixon‐based multisequence and multiplanar MRI for whole‐body detection of cancer metastases 2009 ·Journal of Magnetic Resonance Imaging ·Jingfei Ma, Colleen M. Costelloe, John E. Madewell, Gabriel N. Hortobágyi, Marjorie C. Green, Guangwen Cao, Fei Sun, Vikas Kundra	32
12	Triple Receptor–Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes 2008 ·Journal of Clinical Oncology ·Shaheenah Dawood, Kristine Broglio, Shu‐Wan Kau, Marjorie C. Green, Sharon H. Giordano, Funda Meric‐Bernstam, Thomas A. Buchholz, Constance T. Albarracin, Wei Yang, Bryan T. Hennessy, Gabriel N. Hortobágyi, Ana M. González-Angulo	90
13	Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen 2007 ·Clinical Cancer Research ·Aman U. Buzdar, Vicente Valero, Nuhad K. Ibrahim, (unknown), Kristine Broglio, Richard L. Theriault, Lajos Pusztai, Marjorie C. Green, S. Eva Singletary, Kelly K. Hunt, Ayşegül A. Şahin, Francisco J. Esteva, W. Fraser Symmans, Michael S. Ewer, Thomas A. Buchholz, Gabriel N. Hortobágyi	346
14	Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy 2006 ·Annals of Surgical Oncology ·Florentia Peintinger, Henry M. Kuerer, K. Anderson, Judy C. Boughey, Funda Meric‐Bernstam, S. Eva Singletary, Kelly K. Hunt, Gary J. Whitman, T.W. Stephens, Aman U. Buzdar, Marjorie C. Green, W. Fraser Symmans	66
15	Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer breakdown → 2005 ·Journal of Clinical Oncology ·Aman U. Buzdar, Nuhad K. Ibrahim, (unknown), Daniel J. Booser, Eva Thomas, Richard L. Theriault, Lajos Pusztai, Marjorie C. Green, Banu Arun, Sharon H. Giordano, Massimo Cristofanilli, Debra Frye, Terry L. Smith, Kelly K. Hunt, S. Eva Singletary, Ayşegül A. Şahin, Michael S. Ewer, Thomas A. Buchholz, Donald A. Berry, Gabriel N. Hortobágyi	867
16	Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks 2005 ·Journal of Clinical Oncology ·Marjorie C. Green, Aman U. Buzdar, Terry Smith, Nuhad K. Ibrahim, Vicente Valero, (unknown), Massimo Cristofanilli, Daniel J. Booser, Lajos Pusztai, Edgardo Rivera, Richard L. Theriault, Cynthia Carter, Debra Frye, Kelly K. Hunt, W. Fraser Symmans, Eric A. Strom, Ayşegül A. Şahin, William M. Sikov, Gabriel N. Hortobágyi	324
17	Neoadjuvant Chemotherapy 2004 ·Breast Disease ·Marjorie C. Green, Francisco J. Esteva, Gabriel N. Hortobágyi	3
18	Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma 2003 ·Cancer ·W. Fraser Symmans, Mark Ayers, Edwin Clark, James Stec, Kenneth R. Hess, Nour Sneige, Thomas A. Buchholz, Savitri Krishnamurthy, Nuhad K. Ibrahim, Aman U. Buzdar, Richard L. Theriault, (unknown), Eva Thomas, Karin Gwyn, Marjorie C. Green, (unknown), Gabriel N. Hortobágyi, Lajos Pusztai	140
19	Adjuvant chemotherapy for breast cancer 2002 ·Langenbeck s Archives of Surgery ·Marjorie C. Green, Gabriel N. Hortobágyi	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact